India is aiming to build a $120 billion pharmaceutical industry by strengthening exports, accelerating innovation, and expanding domestic manufacturing. The strategy aligns with the country’s ambition to become a global hub for affordable medicines, vaccines, and advanced pharmaceutical products.
The sector’s growth is expected to be driven by rising exports, increased investments in research and development, and the adoption of advanced technologies in drug manufacturing. Government initiatives supporting bulk drug production, medical devices, and pharmaceutical innovation are also expected to enhance the industry’s global competitiveness.
Indian pharmaceutical companies are increasingly focusing on high-value segments such as biosimilars, specialty medicines, complex generics, and contract development and manufacturing services (CDMO), while expanding their presence in regulated markets, including the United States and Europe.
Industry stakeholders believe that continued policy support, improved regulatory standards, and greater investment in innovation will be critical to achieving the $120 billion target. Expanding manufacturing capacity and strengthening supply chain resilience are also expected to play a key role in sustaining long-term growth.
With a strong manufacturing base, a skilled workforce, and a growing global footprint, India’s pharmaceutical sector is well positioned to reinforce its status as one of the world’s leading suppliers of quality and affordable medicines.